Immunovant Earnings Estimate

IMVT -  USA Stock  

USD 8.10  0.20  2.41%

Many public companies, such as Immunovant, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Immunovant's earnings estimates, investors can diagnose different trends across Immunovant's analyst sentiment over time as well as compare current estimates against different timeframes.
Immunovant is projected to generate -1.24 in earnings per share on the 31st of December 2022. Immunovant earnings estimates module stress-tests analyst consensus about projected Immunovant EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Risk vs Return Analysis.

Immunovant Earnings Estimates 

 
Refresh

Immunovant Earnings Estimation Breakdown

Calculation of earning per share of Immunovant is based on official Zacks consensus of 4 analysts regarding Immunovant future annual earnings. Given the historical accuracy of 82.39%, the future earnings per share of Immunovant is estimated to be -1.24 with the lowest and highest values of -1.63 and -1.09, respectively. Please note that this consensus of annual earnings estimates for Immunovant is an estimate of EPS before non-recurring items and including employee stock options expenses
Current EPS
-1.18
25th of October 2021
-1.63
Lowest
Estimated EPS
-1.24
-1.09
Highest

Immunovant Earnings Projection Consensus

Suppose the current estimates of Immunovant's value are higher than the current market price of the Immunovant stock. In this case, investors may conclude that Immunovant is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immunovant's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2022

4

82.39%

-1.18

-1.24

Immunovant Earnings per Share Projection vs Actual

Actual Earning per Share of Immunovant refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Immunovant predict the company's earnings will be in the future. The higher the earnings per share of Immunovant, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Immunovant Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Immunovant, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Immunovant should always be considered in relation to other companies to make a more educated investment decision.

Immunovant Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Immunovant's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-09
2021-06-30-0.3167-0.310.0067
2021-06-01
2021-03-31-0.338-0.290.04814 
2021-02-16
2020-12-31-0.2548-0.32-0.065225 
2020-11-12
2020-09-30-0.3043-0.250.054317 
2020-08-12
2020-06-30-0.322-0.38-0.05818 
2020-06-29
2020-03-31-0.28-0.38-0.135 
2020-02-14
2019-12-31-0.255-0.28-0.025

About Immunovant Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Immunovant earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Immunovant estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Immunovant fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-198.7 M-203.9 M
Earning Before Interest and Taxes EBIT-107.8 M-110.6 M
Earnings per Basic Share(1.22) (1.32) 
Earnings per Diluted Share(1.22) (1.32) 
Price to Earnings Ratio(13.15) (14.19) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-106.8 M-115.2 M
Earnings before Tax-107.8 M-116.3 M
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people.

Immunovant Investors Sentiment

The influence of Immunovant's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunovant. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - IMVT

Immunovant Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunovant. What is your judgment towards investing in Immunovant? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunovant using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Is Immunovant's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunovant. If investors know Immunovant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.